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doi:10.1016/j.ejvs.2011.06.026Abstract Objective: The aims of our study were to confirm the effectiveness via animal study
and safety through clinical trials of using human cord blood-mononuclear cells (HCB-MNCs).
Design: We performed a doseeresponse animal study (HCB-MNCs: 4  106, 4  107 and 4  108)
using a limb ischaemia model in dogs to assess angiogenic responses. Safety assessment in hu-
mans in terms of graft-versus-host-disease was also done by observing an uncontrolled case
series.
Materials and methods: Twelve animal ischaemic limbs and seven patients with thromboangii-
tis obliterans were treated with HCB-MNCs. These cells (4  108) were injected into the ischae-
mic limb muscle of patients. The results were analysed at 8 weeks for the animal study and at 6
months for patients.
Results: In the animal ischaemic models, the number of capillaries, angiogenic gene expres-
sion and the angiogenic factors were increased after HCB-MNC injection. In the clinical study,
the seven patients experienced no graft-versus-host-disease or cardiac/cerebral complications
during the follow-up period.
Conclusion: This preliminary study suggests that HCB-MNC might be a safe source of stem cells
for treating ischaemic limbs. However, further clinical studies are needed to establish the
long-term safety and the clinical efficacy of HCB-MNC transplantation in patients with ischae-
mic limbs.
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668 A.-K. Kim et al.Stem-cell therapy for peripheral arterial occlusive
disease is one of the new frontiers in the field of clinical
research. Even though there have been many adult-stem-
cells’ studies in animal models, few studies have
attempted to study stem cells transplantation in patients
with ischaemic limbs.1 A small number of recently
reported studies have used stem-cell-based therapeutic
angiogenesis in patients with critical limb ischaemia,2
and stem-cell-based therapeutic angiogenesis has
a potentially promising future for the treatment of
ischaemic diseases, such as thromboangiitis obliterans
(Burger’s disease).2 This type of therapy has shown
promise for developing new blood vessels in patients who
have critical limb ischaemia and who cannot undergo
either bypass or percutaneous revascularisation.3 Human
umbilical cord blood (HCB) is an attractive source of stem
cells to induce angiogenesis. Human cord blood-derived
mononuclear cells (HCB-MNCs) have also been proposed
for use as regenerative therapy in patients with ischae-
mic disease of the heart and limbs.4 HCB-MNCs should be
associated with less graft-versus-host-disease (GVHD) and
the human leucocyte antigen (HLA) matching should be
less stringent because of the immunological naivete´ of
HCB-MNCs.5,6
In the present study, we studied the safety and the
efficacy of transplanting HCB-MNCs for inducing angiogen-
esis in the ischaemic limbs of an animal model and also in
patients with thromboangiitis obliterans. We also evaluated
the differences in capillary number and angiogenic gene
and cytokine expression, according to the different
numbers of HCB-MNC cells administered.
Materials and Methods
Ethics and approval
The animal study was reviewed and approved by the Insti-
tutional Animal Care and Use Committee of Samsung
Biomedical Research Institute (SBRI). The institute is
a member of the Association for the Assessment and
Accreditation of Laboratory Animal Care (AAALAC) Inter-
national Accredited Facilities, and it abides by the Institute
of Laboratory Animal Resource’s guidelines.
The clinical study was approved by the Institutional
Review Board (www.eirb.com) of our hospital, and we
obtained written informed consent for participation from
all the enrolled patients.
HCB-MNCs’ isolation and characterisation
The HCB samples were obtained from the umbilical vein
immediately after delivery with the informed consent of
the donor. The HCB-MNCs were isolated using 10% CPDA/
PBS (citrate-phosphate-dextrose-adenine)/(phosphate-
buffered saline). The pure HCB-MNCs were injected into
the animal models and the clinical patients, and these
cells were analysed by performing fluorescence activated
cell sorting (FACS). The isolated cells for the clinical
trials underwent analysis for several viral antigens (hepa-
titis B surface antigen (HBsAg), anti-hepatitis C virus (anti-
HCV), anti-human immunodeficiency virus (anti-HIV),cytomegalovirus immunoglobulin M (CMV IgM), CMV IgG),
TPHA (Treponema pallidium haemagglutination), HLA-A,
HLA-B and HLA-DR, microorganism culture, a CD34þ cell
count, and the ABO type, alanine aminotransferase (ALT),
were also determined.Animal study
The dog ischaemic models
The dog ischaemic models were induced as described
previously.7 Briefly, with the dogs under anaesthesia, the
femoral arteries in both lower limbs were encircled by using
an ameroid constrictor (RISW, CA, USA) with an inner
diameter of 1.5 mm. After 4 weeks, we identified the
complete occlusion of a femoral artery by conducting
a Doppler examination. Cefazolin (20 mg kg1, Chong Kun
Dong, Korea) was injected intra-muscularly (I.M.) 2 times
a day for 3 days.
The HCB-MNCs were transplanted via intramuscular
injection to one of the ischaemic limbs. The other ischae-
mic limb was not injected and was used as a control limb. A
total of 12 dogs were examined. Separate experimental
groups were used for cell doses of 4  106 (n Z 4), 4  107
(n Z 4) and 4  108 (n Z 4).
Angiography and muscle harvest
The dogs were re-anaesthetised 8 weeks after cell trans-
plantation. After exposure of the abdominal aorta,
a contrast dye (Ultravist370, Schering, Korea) was injected
into the abdominal aorta, and then the angiograms of the
limbs were obtained. After angiography, the ischaemic
muscles that underwent cell-injection were harvested for
histological analysis.
Immunofluorescent staining for the endothelial cells
(ECs)’ differentiation
For the detection of human cells and endothelial cells
(ECs), the harvested fresh muscle tissues were immuno-
fluorescently stained with monoclonal mouse anti-human
nuclear antigen antibody (HNA, Chemicon MAB 1281) and
polyclonal rabbit anti-human von Willebrand Factor anti-
body (vWF, Dako, Glostrup, Denmark). After incubation
with the secondary antibody (fluorescein isothiocyanate
(FITC) and Texas red), the sections were mounted with 6-
diamidino-2-phenylindole (DAPI, Vector Laboratories,
Burlingame).
Immunohistochemical staining for detecting angiogenic
factors
Immunohistochemical staining was performed as described
previously.8 The blocked sections were incubated with the
primary antibodies anti-human vWF, anti-human vascular
endothelial growth factor (VEGF), anti-human proliferating
nuclear cell antigen (PCNA), anti-human platelet-derived
growth factor (PDGF), anti-human basic fibroblast growth
factor (bFGF) and anti-human P-AKT for 1 h at room
temperature (RT) (Dako, Glostrup, Denmark). The sections
were then incubated with the EnVisionþ Systems polymer-
conjugated secondary antibody (Dako, Glostrup,
Denmark), and they were finally incubated with dia-
minobenzidine (DAB).
HCB-MNC Transplantation in Ischaemic Limbs 669Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin neck-end labelling (TUNEL) assay for detecting
apoptosis cells
The apoptotic nuclei were assessed in the muscle cross-
sections via a terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate (dUTP)-biotin neck-end
labelling (TUNEL) assay. The apoptotic nuclei were identified
by an apoptosis detection kit (ApoTag Plus Peroxidase In
Situ Apoptosis Detection Kit, Co. S7101, Chemicon),
according to themanufacturer’s instructions formuscle cross-
sections.
Western blotting for detecting angiogenic factors
The protein that was separated by performing sodium
dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was incubated with specific antibodies over-
night at 4 C, and then the protein was reacted with
horseradish peroxidase (HRP) goat anti-mouse Ig (BD,
Franklin Lakes, NJ, USA), polyclonal goat anti-rabbit
antibody (Dako, Glostrup, Denmark) or polyclonal
rabbit anti-goat antibody (Dako). The reaction was
developed using the Enhanced Chemiluminescence
Detection System (ECL, Amersham, Piscataway, NJ, USA)
and X-ray film.
Real-time-quantitative polymerase chain reaction (qPCR)
for detecting angiogenic genes
The total RNA was isolated from the harvested ischaemic
tissues. The complementary DNA (cDNA) was mixed with
SYBR Green Realtime PCR Master Mix (Toyobo Co., Ltd.,
Osaka, Japan) and the primers. The primers are shown in
Table 1. The temperature cycling and real-time fluores-
cence measurement was done using the real-time PCR
quantitation system (ABI 7000: Applied Biosystems)
according to the manufacturer’s instructions. The relative
quantitation of the gene expression was done by using the
comparative CT (DDCT) method.
9
The capillary and the cytokine-positive cell counts
The five fields from the harvested ischaemic tissues were
randomly selected, and presentative microscope
(Olympus BX50F) images taken with a camera (Pixera
penguin 600CL). Then, the number of capillaries and
cytokine-positive cells in each field (1.4 mm2) were coun-
ted and measured with using the Image-pro plus 6.2
program10 (MediaCybernetics).Table 1 RT-qPCR primers.
VEGF Sense 50-GGAGATGAGTTTCCTGCAGCATAGC-30
Anti-sense 50-ACAGGGAACGCTCCAGGGTTTAT-30
vWF Sense 50-GTGACCCTGAGCACTGCCAAAT-30
Anti-sense 50-CCACATACGAGGTGGTAGAGCCAA-30
PDGF Sense 50-CACGAGGGAGTGGGGATCAGATA-30
Anti-sense 50-GCGTCTGAATGAGGCACTTCCA-30
CD31 Sense 50-TCAAGACAGGAAGCTGTTTGCCT-30
Anti-sense 50-TCCACTCACTCAAGGCACCATCA-30
GAPDH Sense 50-CATCACTGCCACCCAGAAG -30
Anti-sense 50-GAAGGCCATGCCAGTGAG-30Clinical trials
Patients
Seven patients (seven lower limbs) who had thromboangiitis
obliterans (TAO) with the symptoms of intermittent clau-
dication, ischaemic rest pain and ischaemic foot ulcer for
a minimum of 3 months (without evidence of improvement
with medical treatment) were enrolled in the present
study. The TAO was diagnosed by Shionoya’s criteria.11 All
the patients were taking at least one medicine, such as
prostaglandins or cilostazol, and the medication was
unchanged during the study period. The exclusion criteria
were an age more than 60 years, a previous (<5 years) or
current history of malignant disease and the refusal or
inability to give informed consent.
The cell-transplantation procedure and follow-up
A total of 4  108 ABO type-matched HCB-MNCs were
injected into 20 sites of the ischaemic calf muscles along
the tibial and peroneal arteries.
After the procedures, the patients were followed up at
1, 3, 6 and 9 months. For evaluating the safety of trans-
planting the HCB-MNCs, the patients were carefully moni-
tored for any clinical manifestations that would suggest
adverse events such as graft-versus-host-disease (GVHD)
and cardiac and cerebral complications. The laboratory
examinations, including a complete blood count, liver
function tests, renal function tests and urine analysis, were
performed at the 3- and 6-month visits. The patients did
not receive any immunosuppressive drugs.
Assessment
The ischaemic symptoms were classified according to the
‘Recommended Standards Guideline’, as described previ-
ously.12 Further, the safety assessment in humans in terms
of GVHD was analysed by observing an uncontrolled case
series. The safety assessment was done in a non-blind
manner.
Statistical analysis
The results were expressed as means  SDs, and 95%
confidence interval (CI) were calculated, if necessary.
Comparisons of the positive-cell-count results among
treatment groups, between control and each treatment
were tested using the mixed model,13 due to repeated
measurements per subject. P-values from group compari-
sons were adjusted with Bonferroni’s correction due to
multiple comparisons. All statistical analysis was performed
with SAS version 9.13, and a p-value <0.05 was considered
as statistically significant.
Results
Animal study
The isolated HCB-MNCs were directly analysed by FACS. The
CD34 marker of the ECs was found on 0.41% of the total
MNCs (Fig. 1). We identified the differentiation of the ECs
from the HCB-MNCs in Fig. 2.
At 8 weeks after HCB-MNC transplantation, the angio-
genic effects were analysed according to the numbers of
Figure 1 The characteristics of the HCB-MNCs. The CD34, CD45 and Mouse IgG markers used for the FACS data of the HCB-MNCs.
The CD34 marker of endothelial cells (EC) was found on 0.41% of the total mononuclear cells.
670 A.-K. Kim et al.transplanted cells, such as 4  106, 4  107 and 4  108
HCB-MNCs. The typical examples of angiographies are
shown in Fig. 3(A). Capillaries were identified by the
immunohistochemical staining using anti-human vWF
(Fig. 3(B)). The capillary numbers were higher in the
treated limbs than in the control limbs (4  106:
87.25  14.56 vs 70.1  8.48, p Z 0.002, 4  107:
97.15  19.87 vs 53.95  9.49, p Z 0.0024 and 4  108:
84.35  15.39 vs 54.15  13.26, p Z 0.0003, respectively)
(Table 2). The ratio of capillaries to muscle fibre in treated
versus untreated limb was 1.33  0.13, p Z 0.0006:
1.31  0.09, p Z 0.0108 and 1.27  0.16, p < 0.0001,
following administration of 4  106, 4  107 and 4  108
HCB-MNC, respectively (Table 2).
Determination of angiogenic proteins was conducted by
immunohistochemical staining and Western blotting.
TUNEL-positive cell numbers of the treated limbs were
significantly decreased compared with the control limbs
(Table 2). Angiogenic factors (PDGF, VEGF, bFGF and P-AKT)
and PCNA-positive cell numbers in the treated limbs were
significantly increased compared to the control limbs
(Table 2). The differences in the numbers of capillary and
angiogenic factors-positive cells among the treated groupsFigure 2 Identification of differentiation into endothelial cells. A
for the endothelial cells, and a red signal was tagged to the hum
injected into the muscle tissue at 8 weeks after cell transplant
endothelial cells of the capillaries from the transplanted cells. Scaare summarised in Table 3. On Western blotting, samples
from treated limbs of the 4  106, 4  107 and 4  108
groups showed high VEGF, Ang-1, signal transducer and
activator of transcription 3 (STAT3) and P-AKT protein
expression, but after administration of the highest dose
(4  108) phosphorylated extracellular signal-regulated
kinase (p-ERK), Tie-1 and p-STAT3 expressions declined
(Fig. 4). The angiogenic gene expression in treated group
compared to the control group were analysed in four
animals which were administered 4  107 HCB-MNC
(Table 4). The ratio of angiogenic gene expression
between the treated group and the control group was
2.42  0.04 (pZ 0.005) for VEGF, 3.89  0.32 (pZ 0.0001)
for vWF, 1.10  0.10 (p Z 0.043) for CD31 and 2.35  0.14
(p Z 0.024) for PDGF. The angiogenic gene expression was
analysed 3 times repeatedly from a sample of each animal.Clinical study
Seven patients (seven limbs) with TAO underwent HCB-MNC
transplantation. All the patients were male, and their mean
age was 39  11 years (range: 24e50 years) (Table 5).green signal (FITC) was tagged to the anti-human vWF antibody
an nuclear antibody (HNA; Alexa-594) for detecting the cells
ation. The green/red merged signals were the differentiated
le bars: 50 mm.
Figure 3 The angiogenesis effect of 4  106, 4  107 and 4  108. HCB-MNCs in the dog ischaemia model. (A) The angiography
results. All of the treated limbs showed improved vascularity, as compared with that of the control limbs. Left; 4  106 trans-
planted group, Middle; 4  107 transplanted group, Right: 4  108 transplanted group. (B) Immunohistochemical staining (400).
Capillaries were identified by the immunohistochemical staining using anti-human vWF.
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infection and arterial injury, were reported during the
study period.
Any death, cardiac events or cerebrovascular events did
not occur during the follow-up period. The laboratory
findings, including the complete blood count, total bili-
rubin, aspartate transaminase (AST), alanine transaminase
(ALT), alkaline phosphatase (ALP), creatinine, urine
albumin and urine bilirubin, were maintained within the
normal range during the study period (Table 6). In addition,
the vital signs, including blood pressure (121  17/78  17
and 122  19/77  14 mmHg, respectively), heart rate
(68  10 and 66  8 per min, respectively) and body
temperature (36.1  0.2 and 36.1  0.3 C, respectively)
did not show any significant change during the pre- and
postprocedural period.
To evaluate the development of GVHD after HCB-MNC
transplantation, the development of clinical manifestations
suggesting GVHD, such as skin, liver and gastrointestinal
symptoms, was monitored, and the laboratory tests were
repeated at 3 and 6 months after HCB-MNC administration.
One patient complained of an itching sensation in the
forehead, scalp, thigh and buttock areas without a skin rash
at 6 days after HCB-MNC transplantation and was referred
to a dermatologist. He was diagnosed with acute urticaria,
and he recovered after 3 days of taking antihistamines.
Discussion
The number of stem cells administered is an important
issue for conducting therapeutic angiogenesis, but thereare no gold-standard guidelines for this. We found that
4  107 HCB-MNCs showed a good angiogenic effect in dogs
that weighed 25 kg. Therefore, we administered 4  108
HCB-MNCs for patients weighing 60 kg. The need for
immunosuppression during stem-cell transplantation
remains a matter of hot debate. Tacrolimus has been used
as an immunosuppressive agent in heart, lung and liver
transplantation.14,15 The patients who underwent bone-
marrow cell administration received intensive chemo-
therapy or irradiation.1 However, HCB-MNCs have better
applicability as a donor cell source because of the less
stringent HLA-matching requirements due to the immuno-
logic inertness of the cells and the resultant lower chance
of GVHD.16 Therefore, no immunosuppressive drugs were
given to either the dogs or the human patients in our
studies.
Angiogenesis has been described as the development of
new capillaries from pre-existing vessels, which results in
the formation of new capillary networks.17 It is currently
known that angiogenesis can be induced by several types of
cells and cytokines in both ischaemic animal models and
humans.7
HCB, including the circulating stem cells, such as endo-
thelial progenitor cells, is an attractive cell source for
tissue regeneration, and it is now widely accepted as
a source of cells to promote angiogenesis.18 In this study, as
shown in Fig. 2, we confirmed that the ECs of the newly
developed vessels had differentiated from the HCB-MNCs
administered. Recent studies have showed that the angio-
genic effects of HCB-MNCs are not just due to their
differentiation into ECs but also result from the ability of
Table 2 Number of capillary and positive cells: Comparison between control and treated limbs.
Capillary
density per
areab
Capillary/
Muscle fibreb
Number of positive staining cellsb
TUNEL PDGF VEGF bFGF P-AKT PCNA
Number of injected cell 4  106 Control 70.15  8.48 0.99  0.14 34.35  6.03 6.25  2.15 10.00  1.52 13.35  2.23 7.25  1.16 5.25  1.41
Treatment 87.25  14.56 1.33  0.13 28.70  8.74 9.15  1.42 14.00  1.62 27.30  3.74 9.50  1.15 7.60  1.79
p-valuea 0.0040 0.0012 0.0018 0.0115 0.0119 0.0001 0.0002 0.0083
4  107 Control 53.95  9.49 0.83  0.73 36.35  6.81 5.75  1.25 13.00  1.78 21.30  2.53 5.75  1.33 6.50  1.85
Treatment 97.15  19.87 1.31  0.09 25.60  5.26 15.25  2.84 18.75  1.33 26.05  2.30 15.25  2.45 10.00  2.29
p-valuea 0.0048 0.0216 0.0048 0.002 <0.0001 0.0005 0.0003 0.0082
4  108 Control 54.55  13.26 0.77  0.14 35.05  6.14 5.75  1.41 15.20  2.69 24.95  2.44 5.75  1.41 5.00  1.52
Treatment 84.35  15.39 1.27  0.16 20.65  3.96 11.45  1.95 16.05  1.70 28.50  2.96 11.50  1.43 14.50  2.54
p-valuea 0.0006 <0.0001 0.0035 0.0051 0.0335 0.0372 0.004 <0.0001
a Analysis using the mixed model with Bonferroni’s correction due to multiple testing.
b The numerical values were the numbers of the positive staining cells per 1.4 mm2 area.
Table 3 Number of capillaries and cells staining for angiogenic markers: Comparison among the treated limbs.
Capillary density
per areab
Capillary/
Muscle fibreb
Number of positive staining cellsb
TUNEL PDGF VEGF bFGF P-AKT PCNA
Number of
injected cell
4  106
vs 4  107
Number 87.25  14.56
vs 97.15  19.87
1.33  0.13
vs 1.31  0.09
28.70  8.74
vs 25.60  5.26
9.15  1.42
vs 15.25  2.84
14.00  1.62
vs 18.75  1.33
27.30  3.74
vs 26.05  2.30
9.50  1.15
vs 15.25  2.45
7.60  1.79
vs 10.00  2.29
p-valuea 1.0000 1.0000 0.0030 <0.0001 <0.0001 0.466 <0.0001 <0.0001
4  107
vs 4  108
Number 97.15  19.87
vs 84.35  15.39
1.31  0.09
vs 1.27  0.16
25.60  5.26
vs 20.65  3.96
15.25  2.84
vs 11.45  1.95
18.75  1.33
vs 16.05  1.70
26.05  2.30
vs 28.50  2.96
15.25  2.45
vs 11.50  1.43
10.00  2.29
vs 14.50  2.54
p-valuea 0.8208 0.0096 0.0129 0.0015 <0.0001 0.0495 0.0015 <0.0001
4  106
vs 4  108
Number 87.25  14.56
vs 84.35  15.39
1.33  0.13
vs 1.27  0.16
28.70  8.74
vs 20.65  3.96
9.15  1.42
vs 11.45  1.95
14.00  1.62
vs 16.05  1.70
27.30  3.74
vs 28.50  2.96
9.50  1.15
vs 11.50  1.43
7.60  1.79
vs 14.50  2.54
p-valuea 1.0000 0.840 0.0060 0.00387 0.00186 0.836 0.0078 <0.0001
4  106
vs 4  107
vs 4  108
Number 87.25  14.56
vs 97.15  19.87
vs 84.35  15.39
1.33  0.13
vs 1.31  0.09
vs 1.27  0.16
28.70  8.74
vs 25.60  5.26
vs 20.65  3.96
9.15  1.42
vs 15.25  2.84
vs 11.45  1.95
14.00  1.62
vs 18.75  1.33
vs 16.05  1.70
27.30  3.74
vs 26.05  2.30
vs 28.50  2.96
9.50  1.15
vs 15.25  2.45
vs 11.50  1.43
7.60  1.79
vs 10.00  2.29
vs 14.50  2.54
p-valuec 0.0336 <0.0001 0.0031 <0.0001 <0.0001 0.0411 <0.0001 <0.0001
a Analysis using the mixed model with Bonferroni’s correction due to multiple testing and multiple comparisons.
b The numerical values were the numbers of the positive staining cells per 1.4 mm2 area.
c Analysis using the mixed model with Bonferroni’s correction due to multiple testing.
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Figure 4 Angiogenic factors detection for Western Blotting
The PDGF, P-AKT, VEGF, bFGF and PCNA levels were increased
in the treated limbs according to the cell count, but the
apoptotic nuclei were decreased in the treated limbs as
compared with that of the control limbs.
Table 4 Ratio of the angiogenic gene expression between
treated (4  107 cell group) and control limbs.
VEGF vWF CD31 PDGF
Ratio 2.42  0.04 3.89  0.32 1.10  0.10 2.35  0.14
p-valuea 0.0054 0.0001 0.0438 0.0243
a Analysis using the mixed model.
HCB-MNC Transplantation in Ischaemic Limbs 673these cells to produce various angiogenic growth factors,
including VEGF, bFGF and PDGF.19 Even though HCB-MNCs
may not directly affect the vasculature at the ischaemic
sites, HCB-MNC transplantation may have beneficial effects
in ischaemic tissues due to the release of growth factors,
cytokines, nitric oxide or other factors that limit the tissue
damage and the remodelling that common occurs after
ischaemia.20Table 5 Demographics of the patients and the injected HCB-M
Patients No. 1 2 3
Age/Gender 41/M 35/M 50/M
Symptoms Foot ulcer Moderate
Claudication
Severe
Claudic
HCB-MNCs
condition
HBsAg Negative Negative Negativ
Anti-HCV Negative Negative Negativ
Anti-HIV Negative Negative Negativ
CMV IgM Negative Negative Negativ
CMV IgG Positive Positive Positive
TPHA Negative Negative Negativ
ALT (U/L) 7 4 8
Microorganism
Culture
No growth No growth No grow
CD34 (106) 5.99 7.19 4.71
TPHA (Treponema Pallidium Haemagglutination), ALT (alanine aminotIntramuscular injection (I.M.) of stem cells is considered
more effective than intra-arterial injection (I.A.).21 We also
observed that I.M. administration was more effective in our
dog model, where after 8 weeks, the capillary density was
79  7.45 after I.M. administration compared with
58  5.25 after I.A. administration of equivalent cell
numbers.
The numbers of the positive cells on TUNEL assay
decreased, and the numbers of the PCNA-positive cells
increased as the numbers of injected stem cell increased.
This result suggested that the survival and proliferation of
stem cells were influenced by the numbers of injected stem
cells. However, the capillary density and number of
angiogenic-marker-positive cells were higher in the 4  107
group than the other cell groups. This suggests that the
optimal size of the stem-cell injection was between 4  107
and 4  108 cells in dogs weighing about 25 kg.
HCB has been reported to be a source of allogeneic stem
cells to transplant for reconstituting the immune
system.21,22 HCB transplantation is being increasingly used
in the clinical field. It has been shown that HCB contributed
to the lower incidence of GVHD as compared with other
sources of adult stem cells. There was no clear association
between HLA matching and survival.5,16 Our study also
showed there were no side effects in terms of the immune
response after HCB-MNC administration in either dogs or
humans.
TAO is a non-atherosclerotic, segmental inflammatory
occlusive disease that affects the medium- and small-sized
arteries of the legs and/or arms.23 Although the exact
mechanism is currently unknown, the use of tobacco is
strongly associated with the initiation and progression of
TAO.24 In TAO, the conventional procedures used for
peripheral arterial occlusive disease, such as arterial
bypass or percutaneous transluminal angioplasty, are not
suggested, and they are usually unsuccessful because of the
diffuse segmental occlusion and the occlusion of the small-
to medium-sized arteries.25 Therefore, additional treat-
ment modalities are required to relieve the ischaemic
symptoms and salvage the limb. There have been only
limited studies that have used stem cells in patients withNC conditions.
4 5 6 7
27/M 25/M 47/M 50/M
ation
Moderate
Claudication
Severe
Claudication
Severe
Claudication
Rest
pain
e Negative Negative Negative Negative
e Negative Negative Negative Negative
e Negative Negative Negative Negative
e Negative Negative Negative Negative
Positive Positive Positive Positive
e Negative Negative Negative Negative
6 3 4 7
th No growth No growth No growth No growth
3.25 8.09 6.41 2.12
ransferase).
Table 6 Safety Evaluation Items of the Patients.a
Before
HCB-MNC
transplantation
1 day after
HCB-MNC
transplantation
12 weeks after
HCB-MNC
transplantation
24 weeks after
HCB-MNC
transplantation
WBC (/ml) 7954  3302 6903  1860 6010  2290 7863  2414
Hb (g/dL) 15.0  1.4 14.5  1.4 15.3  1.0 14.9  0.7
Platelet (/ml) (103) 269  34 229  50 237  30 248  54
Albumin (g/dL) 4.6  1.2 4.0  0.4 4.2  0.2 4.1  0.2
T-Bil (mg/dL) 0.6  0.2 0.6  0.2 0.7  0.3 0.5  0.1
AST (U/l) 22  8 25  15 22  8 23  6
ALT (U/l) 32  13 39  26 31  16 32  15
ALP (U/l) 65  19 67  20 68  18 68  20
BUN (mg/dL) 13.2  4.6 9.6  2.2 12.5  2.5 11.8  3.0
Creatinine (mg/dL) 0.88  0.1 0.88  0.07 0.92  0.07 0.89  0.10
Uric Acid (mg/dL) 5.3  1.3 4.9  1.1 5.5  1.6 5.3  0.7
Naþ (mmol/l) 143  2 142  2 143  2 142  2
Kþ (mmol/l) 4.2  0.3 4.2  0.2 4.2  0.5 4.2  0.4
a Albumin, bilirubin and nitrite were not detected in the urine of any patients.
674 A.-K. Kim et al.ischaemic limbs. Durdu and Motukuru et al. have reported
that stem-cell therapy using autologous mononuclear cells
in patients with TAO facilitates angiogenesis and improves
the ischaemic symptoms.26 To assess the efficacy of the
stem-cell therapy, objective criteria, such as a change of
ischaemic symptoms and a scoring system of angiogenesis,
might be needed.
In conclusion, this preliminary study suggests that HCB-
derived MNCs might provide a safe source of stem cells for
treating ischaemic limbs. However, further clinical studies
are needed to establish long-term safety and clinical effi-
cacy of HCB-MNC transplantation in patients with ischaemic
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